Just What is Discovery Medicine? And What Does it Mean for HIV Vaccine Research?
Participants joined to gain a broad understanding of Discovery Medicine including an overview of the current landscape for HIV vaccines. We also discussed what it means for HIV vaccine research and development moving forward, with a focus on community and advocacy priorities.
Speakers:
Dr. Betty Mwesigwa, Makerere University Walter Reed Project
Tian Johnson, BRILLIANT HIV Vaccine Discovery Consortium
Dr. Cathy Slack, HIV AIDS Vaccines Ethics Group
Dr. Sandhya Vasan, Henry M. Jackson Foundation for the Advancement of Military Medicine, US Military HIV Research Program
Moderators:
Stacey Hannah, AVAC
Louis Shackelford, HIV Vaccine Trials Network (HVTN) & COVID-19 Prevention Network (CoVPN)
HIV self-testing (HIVST) is a safe, accurate, and effective alternative to provider-administered testing that many users prefer for its convenience and confidentiality. At IAS 2023, WHO issued a new recommendation to offer HIVST for PrEP initiation and continuation as an innovative way to increase PrEP access and coverage and further simplify PrEP delivery. However, many implementers still have questions on how to effectively roll out and scale up this important self-care intervention.
On May 23, AVAC and WHO hosted a webinar to learn more about WHO guidance on use of HIVST and to hear directly from a panel of experts on their experiencing rolling out HIVST for PrEP, guidance on procurement and costing, and more.
We Can’t End HIV in the United States Without Equitable PrEP Access: Strategies for success
A collaboration between HIVMA, PrEP4All and The Choice Agenda, this webinar assessed some of the key challenges to delivering PrEP in the United States equitably, including cost, the complexities of our health care system, and other factors that inhibit uptake amongst the most vulnerable communities. Strategies to address these challenges were offered included a Q&A, discussion and much-needed debate.
Speakers: • Dr. Lorraine Dean, Johns Hopkins University, Department of Epidemiology • Dr. Rupa Patel, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention • Dr. Patrick Sullivan, Rollins School of Public Health, Emory University
Discussing Early Results from the SEARCH Dynamic Choice Study
AVAC and the SEARCH team were joined by Professor Moses Kamya of Makerere University to find out why the early results of the SEARCH Dynamic Choice study were some of the most exciting to come out of CROI in 2024.
Conducted in Kenya and Uganda, the study offered oral PrEP, PEP or injectable cabotegravir to both men and women, and an option to switch products. Prevention services were person-centered, including access to a clinician by phone at any time, clinic and community access to services, and counseling to develop personalized adherence plans. Coverage among study participants increased to 70% (compared to 13% in the standard of care), 28% of participants used two different products during the study, and the study arm ended with zero incidence of HIV compared to 1.8% in the control group. These numbers show why adding to the method mix expands the number of people who continue with prevention—even as their needs change.
The webinar consisted of a presentation by Professor Kamya, followed by a robust discussion about the role of choice in HIV prevention.
It was also the setting for important updates on the HIV reservoir lending to new insights into potential HIV cure strategies. Progress in HIV cure research, as part of a pipeline of biomedical tools to help end the epidemic, must be supported and guided by an advocacy agenda that puts communities first. Read on for cure highlights from CROI, new opportunities for cure advocates, and an upcoming webinar on pediatric cure research with Deborah Persaud and Gabriela Cromhout.
Cure Highlights from CROI – Q&A with AVAC’s Jessica Salzwedel
AVAC’s Jessica Salzwedel who leads our advocacy for HIV cure research and serves as the community engagement coordinator for Research Enterprise to Advance a Cure for HIV (REACH), Immunotherapy for Cure (I4C), and Pediatric Adolescent Virus Elimination (PAVE) shares her highlights from the research presented at CROI and insights into what it means for advocacy in this Q&A.
“Four preclinical and clinical results stood out because they advanced how researchers might tailor cure strategies to optimize the impact for people with HIV. We heard more about the potential role of sex hormones in directing the immune system in a study looking at fetus acquisition of HIV. Another study showed that women may be better candidates for the so-called “block and lock” strategy. We also heard results from the IMPAACT P1115 trial, which showed that early HIV treatment can lead to control of the virus in children. And a nonhuman primate study of adeno-associated virus (AAV), which delivered broadly neutralizing antibodies (bNAbs) may offer a pathway to a scalable, durable control option for pediatric cure. In basic science new data suggests that autologous neutralizing antibodies in some people delay rebound. And finally, we heard about rare T-cells that seem to resist killing, which could be important in developing strategies that could lead to durable control and eradication of HIV. ” Read the Q&A to see what it all means.
Join Us for the 2024 Cure Academy
The Advocacy-for-Cure Academy, organized in partnership with the International AIDS Society, awards fellowships to advocates or peer educators to take part in workshops on HIV cure advocacy with international experts. The academy develops fellows’ cure research literacy and reinforces their advocacy and engagement skills in line with recommendations from Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Applications are now open. Deadline Monday, 25 March 2024. The next Cure Academy runs June 8 – 10, 2024 in eastern Africa.
Language guide for cure: This document shares up-to-date, community-preferred terminology within cure research
Avac Event
The More We Know: Evolving our understanding of PrEP for cisgender women
Science and real-world experience continue to demand a re-assessment of our collective understanding of the safety and effectiveness of PrEP options for women, including oral, vaginal ring, and injectable options. For instance, a new paper in the Journal of the American Medical Association by Dr. Jeanne Marrazzo (HIV Pre-Exposure Prophylaxis with Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women) challenges the notion, baked into policies, programs and “conventional wisdom”, that cisgender women need to be “super-adherers” to achieve protection utilizing oral PrEP. In this webinar, we discussed this important paper and more.
Speakers: • Dr. Jeanne Marrazzo, National Institute of Allergy and Infectious Diseases • Joyce Ng’ang’a, WACI Health
STI Awareness Week Webinar Series (April 16 and 18)
Syphilis in the US: The current state of the epidemic and how it’s being addressed
Tuesday, April 16, 1:00PM ET
This webinar examined the current state of the syphilis epidemic in the US and how the National Syphilis and Congenital Syphilis Syndemic Federal Task Force is addressing the response.
Speakers included: Kate Miele and LCDR Neelam Gazarian
MOSAIC Global PrEP Learning Network – Building a Brand for PrEP: Positioning PrEP in the Hearts and Minds of Young People
With choice of PrEP products on the horizon – including oral PrEP, the PrEP ring, and injectable cabotegravir for PrEP (CAB PrEP) – PrEP marketing and demand generation must evolve with the availability of new PrEP products. Young people, in particular, need PrEP demand generation campaigns tailored to their needs and aspirations. In this webinar, we will hear from teams working to change the landscape of PrEP marketing by applying private sector approaches to brand the PrEP category. We will also hear how they are developing fresh, dynamic, and evidence-informed campaigns to increase PrEP awareness and encourage PrEP use among young people in Africa.
This webinar is being hosted by PEPFAR, USAID, and MOSAIC.
Join us at CROI 2024!
Dear Advocate,
The 31st annual Conference on Retroviruses and Opportunistic Infections (CROI) kicks off this weekend, and runs from March 3-6 in Denver, Colorado. CROI is the go-to forum for groundbreaking science in the HIV field, and this years’ program is full of exciting new research.
At AVAC, we’re tracking data and discussion on long-acting, injectable PrEP; the dapvirine vaginal ring (DVR) in pregnancy; doxycycline as post-exposure prophylaxis (DoxyPEP) to prevent sexually transmitted infections (STIs); and the latest in HIV cure and control. We’re also very excited for this year’s Martin Delaney Presentation – Unveiling the Power of Uganda’s LGBTIQ Advocacy in Shaping HIV Response and Health Care Access – that will be delivered by Frank Mugisha of Sexual Minorities Uganda (SMUG) in Uganda and couldn’t be more timely. Be sure to check out the conference program.
AVAC and partners have worked to follow and explain the research presented at CROI for many years, making the science more accessible, connecting the findings to community priorities, and ensuring civil society and affected communities are represented within the program, and ultimately the research. For those attending or not, this email shares ways to follow along and join in the discussion and debate.
Follow Along Be part of the conversation by following AVAC on X (Twitter) at @hivpxresearch for real-time updates using the conference hashtag #CROI2024, and be sure to sign up and follow our partner, Aidsmap, who will be reporting from the conference.
Community Breakfast Clubs (CROI registration not required Join the CROI Community Liaisons, AVAC, the European AIDS Treatment Group, and partners for daily Community Breakfast Clubs. These virtual webinars feature researchers and advocates discussing some of the most consequential science being presented at CROI. They are open to all, CROI registrants and non-registrants alike.
Monday, 4 March, 7:00am – 8:00am MT (Click here to determine the time in your location.)
Looking forward to seeing you at the daily Breakfast Club sessions and to working together to unpack the research and be sure it is applied!
Best, AVAC
Avac Event
CROI 2024
The 31st annual Conference on Retroviruses and Opportunistic Infections (CROI) took place from March 3-6 in Denver, Colorado. CROI is the go-to forum for groundbreaking science in the HIV field, and this years’ program was full of exciting new research.
AVAC Daily Dispatches
AVAC sent out daily dispatches summarizing each day’s news out of CROI:
The CROI Community Liaisons, AVAC, the European AIDS Treatment Group, and partners for daily Community Breakfast Clubs organized the daily Community Breakfast Club. These virtual webinars featured researchers and advocates discussing some of the most consequential science being presented at CROI.
